The pharmaceutical company Almirall has reached an agreement with the firm GW Pharma to commercialize the drug Sativex, prescribed for spasticity in multiple sclerosis, in Mexico, EFE reported.

Almirall in 2005 obtained the exclusive rights to commercialize Sativex in Europe except in the UK, and now has exclusive rights for distribution in Mexico, where it has had a subsidiary for over a decade, according to the company. “We are excited about our partnership with GW and the initial response of the market to Sativex”, said the Chief Operating Officer of Almirall, Luciano Conde.

Sativex is currently commercialized in countries like Spain, Germany and Denmark and throughout this year future releases are planned in Italy, Sweden, Austria or the Czech Republic.




posted by

Barcelona Air Route Development Committee promotes Barcelona Airport intercontinental flights.